Related Party Transactions

12 Months Ended

Dec. 31, 2021

Master Services agreements with drug discovery companies affiliated with David Grainger

The Centessa Predecessor Group entered into Master Services agreements with certain drug discovery companies affiliated with David Grainger, who was appointed as the Company’s Chief Innovation Officer in October 2021. These companies include RxCelerate Limited, RxBiologics Limited and The Foundry (Cambridge) Limited, of which David Grainger is a director and shareholder. The Company and the Centessa Predecessor Group incurred research and development costs associated with these contracts as follows in the consolidated and combined statements of operations and comprehensive loss (amounts in thousands):


	Successor			Predecessor
		Period from January 30, 2021 through December 31, 2021		Period from January 1, 2021 through January 29, 2021		Twelve Months Ended December 31, 2020		Twelve Months Ended December 31, 2019
Research and development		$	7,148	$	418	$	2,946	$	2,251

Cost Reimbursements

During the period from January 30, 2021 through December 31, 2021, the Company (Successor) reimbursed an aggregate of $1.4 million to several shareholders for costs paid on behalf of the Company (Successor) in connection with acquisition of the Centessa Subsidiaries and the sale of the Company (Successor) Series A preferred shares.